Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bum Steer: Long Term Care Pharmacies Take CMS to Court Over "Steering"

This article was originally published in RPM Report

Executive Summary

Nursing home pharmacy providers finally have some advocates: a First Amendment law firm is suing CMS on their behalf. Providers want to be able to recommend specific Part D plans to their patients. A victory would have a big impact on Part D formularies.

You may also be interested in...



FDA's Unlikely Defenders

The primacy of FDA-approved labeling has an unlikely advocate. The Washington Legal Foundation is joining the EPO coverage dispute to tell CMS not to step into FDA’s turf.

Are Long Term Care Rebates Dangerous?

One CMS official thinks it is time for a new business model in long term care. Eliminating rebates to long-term care providers may be necessary to protect patients and Part D plans.

Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D

The Alzheimer’s Association waged and won a six-month battle to end prior authorization programs for AD medications in three Medicare plans. The skirmish has big implications for future of Medicare formularies— and the balance of power between Big Pharma and managed care.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel